The effect of estrogen replacement on early Parkinson's disease

R. Saunders-Pullman, J. Gordon-Elliott, Michael K. Parides, S. Fahn, H. R. Saunders, S. Bressman

Research output: Contribution to journalArticle

209 Citations (Scopus)

Abstract

Objective: To determine the effect of estrogen in postmenopausal women with early PD. Background: The role of estrogen in PD is highly disputed, with some studies suggesting a prodopaminergic effect and others suggesting an antidopaminergic effect. Owing to controversy and the small sample sizes of prior studies, further investigation is warranted. Methods: A retrospective chart review was carried out from a computerized database of patients at Columbia-Presbyterian, including only women who had symptoms of presumed PD for less than 5 years and who had not yet been on L-dopa at their first visit. Multiple regression was performed to assess the effects of estrogen on disease, measured by total Unified Parkinson's Disease Rating Scale (UPDRS) score, as a function of symptom duration, age at onset, education, smoking, dopamine agonist, and deprenyl use. Results: Of the women who were not on L-dopa and had PD for less than 5 years at their first visit, 34 were found to have received estrogen at some time and 104 had never received estrogen. Excluding the women who had taken dopamine agonists, analysis yielded a multiple regression coefficient of 0.52 (p < 0.001). Estrogen use was negatively correlated with UPDRS score; age at onset and symptom duration were positively correlated (p < 0.05). Conclusions: We found a positive association between estrogen use and lower symptom severity in women with early PD not yet taking L-dopa. These results indicate that estrogen therapy should not be avoided and may be beneficial in early PD, at least prior to the initiation of L-dopa.

Original languageEnglish (US)
Pages (from-to)1417-1421
Number of pages5
JournalNeurology
Volume52
Issue number7
StatePublished - Apr 22 1999
Externally publishedYes

Fingerprint

Estrogen Replacement Therapy
Parkinson Disease
Estrogens
Levodopa
Dopamine Agonists
Age of Onset
Selegiline
Sample Size
Smoking
Databases
Education

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Saunders-Pullman, R., Gordon-Elliott, J., Parides, M. K., Fahn, S., Saunders, H. R., & Bressman, S. (1999). The effect of estrogen replacement on early Parkinson's disease. Neurology, 52(7), 1417-1421.

The effect of estrogen replacement on early Parkinson's disease. / Saunders-Pullman, R.; Gordon-Elliott, J.; Parides, Michael K.; Fahn, S.; Saunders, H. R.; Bressman, S.

In: Neurology, Vol. 52, No. 7, 22.04.1999, p. 1417-1421.

Research output: Contribution to journalArticle

Saunders-Pullman, R, Gordon-Elliott, J, Parides, MK, Fahn, S, Saunders, HR & Bressman, S 1999, 'The effect of estrogen replacement on early Parkinson's disease', Neurology, vol. 52, no. 7, pp. 1417-1421.
Saunders-Pullman R, Gordon-Elliott J, Parides MK, Fahn S, Saunders HR, Bressman S. The effect of estrogen replacement on early Parkinson's disease. Neurology. 1999 Apr 22;52(7):1417-1421.
Saunders-Pullman, R. ; Gordon-Elliott, J. ; Parides, Michael K. ; Fahn, S. ; Saunders, H. R. ; Bressman, S. / The effect of estrogen replacement on early Parkinson's disease. In: Neurology. 1999 ; Vol. 52, No. 7. pp. 1417-1421.
@article{d1102f5a73d540a386bbbac72ead8665,
title = "The effect of estrogen replacement on early Parkinson's disease",
abstract = "Objective: To determine the effect of estrogen in postmenopausal women with early PD. Background: The role of estrogen in PD is highly disputed, with some studies suggesting a prodopaminergic effect and others suggesting an antidopaminergic effect. Owing to controversy and the small sample sizes of prior studies, further investigation is warranted. Methods: A retrospective chart review was carried out from a computerized database of patients at Columbia-Presbyterian, including only women who had symptoms of presumed PD for less than 5 years and who had not yet been on L-dopa at their first visit. Multiple regression was performed to assess the effects of estrogen on disease, measured by total Unified Parkinson's Disease Rating Scale (UPDRS) score, as a function of symptom duration, age at onset, education, smoking, dopamine agonist, and deprenyl use. Results: Of the women who were not on L-dopa and had PD for less than 5 years at their first visit, 34 were found to have received estrogen at some time and 104 had never received estrogen. Excluding the women who had taken dopamine agonists, analysis yielded a multiple regression coefficient of 0.52 (p < 0.001). Estrogen use was negatively correlated with UPDRS score; age at onset and symptom duration were positively correlated (p < 0.05). Conclusions: We found a positive association between estrogen use and lower symptom severity in women with early PD not yet taking L-dopa. These results indicate that estrogen therapy should not be avoided and may be beneficial in early PD, at least prior to the initiation of L-dopa.",
author = "R. Saunders-Pullman and J. Gordon-Elliott and Parides, {Michael K.} and S. Fahn and Saunders, {H. R.} and S. Bressman",
year = "1999",
month = "4",
day = "22",
language = "English (US)",
volume = "52",
pages = "1417--1421",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "7",

}

TY - JOUR

T1 - The effect of estrogen replacement on early Parkinson's disease

AU - Saunders-Pullman, R.

AU - Gordon-Elliott, J.

AU - Parides, Michael K.

AU - Fahn, S.

AU - Saunders, H. R.

AU - Bressman, S.

PY - 1999/4/22

Y1 - 1999/4/22

N2 - Objective: To determine the effect of estrogen in postmenopausal women with early PD. Background: The role of estrogen in PD is highly disputed, with some studies suggesting a prodopaminergic effect and others suggesting an antidopaminergic effect. Owing to controversy and the small sample sizes of prior studies, further investigation is warranted. Methods: A retrospective chart review was carried out from a computerized database of patients at Columbia-Presbyterian, including only women who had symptoms of presumed PD for less than 5 years and who had not yet been on L-dopa at their first visit. Multiple regression was performed to assess the effects of estrogen on disease, measured by total Unified Parkinson's Disease Rating Scale (UPDRS) score, as a function of symptom duration, age at onset, education, smoking, dopamine agonist, and deprenyl use. Results: Of the women who were not on L-dopa and had PD for less than 5 years at their first visit, 34 were found to have received estrogen at some time and 104 had never received estrogen. Excluding the women who had taken dopamine agonists, analysis yielded a multiple regression coefficient of 0.52 (p < 0.001). Estrogen use was negatively correlated with UPDRS score; age at onset and symptom duration were positively correlated (p < 0.05). Conclusions: We found a positive association between estrogen use and lower symptom severity in women with early PD not yet taking L-dopa. These results indicate that estrogen therapy should not be avoided and may be beneficial in early PD, at least prior to the initiation of L-dopa.

AB - Objective: To determine the effect of estrogen in postmenopausal women with early PD. Background: The role of estrogen in PD is highly disputed, with some studies suggesting a prodopaminergic effect and others suggesting an antidopaminergic effect. Owing to controversy and the small sample sizes of prior studies, further investigation is warranted. Methods: A retrospective chart review was carried out from a computerized database of patients at Columbia-Presbyterian, including only women who had symptoms of presumed PD for less than 5 years and who had not yet been on L-dopa at their first visit. Multiple regression was performed to assess the effects of estrogen on disease, measured by total Unified Parkinson's Disease Rating Scale (UPDRS) score, as a function of symptom duration, age at onset, education, smoking, dopamine agonist, and deprenyl use. Results: Of the women who were not on L-dopa and had PD for less than 5 years at their first visit, 34 were found to have received estrogen at some time and 104 had never received estrogen. Excluding the women who had taken dopamine agonists, analysis yielded a multiple regression coefficient of 0.52 (p < 0.001). Estrogen use was negatively correlated with UPDRS score; age at onset and symptom duration were positively correlated (p < 0.05). Conclusions: We found a positive association between estrogen use and lower symptom severity in women with early PD not yet taking L-dopa. These results indicate that estrogen therapy should not be avoided and may be beneficial in early PD, at least prior to the initiation of L-dopa.

UR - http://www.scopus.com/inward/record.url?scp=0033594528&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033594528&partnerID=8YFLogxK

M3 - Article

VL - 52

SP - 1417

EP - 1421

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 7

ER -